Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Nu-9
2. Akv9
3. Ssz5c8u4kq
4. Akv-9
5. Chembl2089305
6. Schembl12676303
7. Fvevqubfqxfsny-qmmmgpobsa-n
8. 1,3-cyclohexanedione, 5-[(1s)-1-[3,5-bis(trifluoromethyl)phenoxy]ethyl]-
9. 5-[(1s)-1-[3,5-bis(trifluoromethyl)phenoxy]ethyl]-1,3-cyclohexanedione
10. 1307262-15-2
| Molecular Weight | 368.27 g/mol |
|---|---|
| Molecular Formula | C16H14F6O3 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 43.4 |
| Heavy Atom Count | 25 |
| Formal Charge | 0 |
| Complexity | 475 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
The funding will support Akava’s lead compound, NU-9 (AKV9). It is being evaluated for the treatment of Alzheimer’s disease and frontotemporal dementia.
Lead Product(s): AKV9
Therapeutic Area: Neurology Brand Name: NU-9
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: National Institute on Aging
Deal Size: $7.3 million Upfront Cash: Undisclosed
Deal Type: Funding December 17, 2024
Lead Product(s) : AKV9
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : National Institute on Aging
Deal Size : $7.3 million
Deal Type : Funding
Akava Therapeutics Celebrates $7.3M Grant to Study AKV9 in Neurodegeneration
Details : The funding will support Akava’s lead compound, NU-9 (AKV9). It is being evaluated for the treatment of Alzheimer’s disease and frontotemporal dementia.
Product Name : NU-9
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 17, 2024
Details:
AKV9 (formerly NU-9) is a Protein aggregation inhibitor, which is being investigated in amyotrophic lateral sclerosis and improve the health of diseased upper motor neurons.
Lead Product(s): AKV9
Therapeutic Area: Neurology Brand Name: AKV9
Study Phase: IND EnablingProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2023
Lead Product(s) : AKV9
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKV9 (formerly NU-9) is a Protein aggregation inhibitor, which is being investigated in amyotrophic lateral sclerosis and improve the health of diseased upper motor neurons.
Product Name : AKV9
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
